Author | Population | Route of Administration | Details of administration | Mortality | |
---|---|---|---|---|---|
Study | Control | ||||
Shirai, 2015 | 1 center, 46 patients, sepsis-induced ARDS | EN | Oxepa | Ensure Liquid | 60 days |
Hall, 2015 | 1 center, 60 patients, sepsis | PN | Omegaven | standard medical care | 28 days |
Burkhart, 2014 | 1 center, 50 patients, sepsis | PN | Omegaven | standard treatment | Hospital |
Gultekin, 2014 | 1 center, 58 patients, severe sepsis or septic shock | PN | Omegaven + ClinOleic | ClinOleic | Unspecified |
Pontes-Arruda, 2011 | 5 centers, 115 patients, early stages of sepsis | EN | Oxepa | Ensure Plus HN | 28 days |
Grau-Carmona, 2011 | 11 centers, 198 patients, septic patients with ALI or ARDS | EN | Oxepa | Ensure Plus HN | Unspecified |
Khor, 2011 | 1 center, 28 patients, severe sepsis | PN | Omegaven | normal saline | normal saline |
Barbosa, 2010 | 1 center, 25 patients, sepsis or SIRS | PN | Lipolus | NuTRIflex Lipid Special | 28 days |
Friesecke, 2008 | 1 center, 166 patients, critically ill patients (115 SIRS, 51 non-SIRS) | PN | Omegaven + Lipofundin | Lipofundin | 28 days |
Pontes-Arruda, 2006 | 1 center, 165 patients, severe sepsis or septic shock | EN | EPA-GLA enriched diet | Control Diet | 28 days |
Grecu, 2003 | 1 center, 54 (15 in ICU) patients, abdominal sepsis | PN | Omegaven + LCT | LCT | ICU |